Eli Lilly’s Omvoh Gains Ground In Ulcerative Colitis And Crohn’s
Eli Lilly’s Omvoh (mirikizumab) is gaining momentum in inflammatory bowel disease (IBD) after new clinical data showed sustained efficacy in ulcerative colitis and promising results in Crohn’s disease. The updated results, presented at a medical conference in October 2026, reinforce Omvoh’s potential to become a leading treatment in a market dominated by AbbVie’s Skyrizi and Johnson & Johnson’s Stelara.
Omvoh was first approved for ulcerative colitis in 2023, and Lilly has been pushing to expand its label into Crohn’s disease. The latest data from the Phase 3 LUCENT program showed that patients treated with Omvoh maintained clinical remission through 52 weeks, with a favorable safety profile. In Crohn’s disease, the VIVID-1 study met its primary endpoints, demonstrating significant improvements in clinical remission and endoscopic response compared to placebo.
Why The IBD Market Is A $20 Billion Prize
The IBD market, which includes ulcerative colitis and Crohn’s disease, is estimated to be worth over $20 billion globally and is growing at a mid-single-digit rate. AbbVie’s Skyrizi is currently the market leader, generating $7.3 billion in sales in 2025, while J&J’s Stelara, though facing biosimilar competition in Europe, still brought in $5.2 billion. Lilly’s Omvoh, with its differentiated mechanism targeting the IL-23 p19 subunit, could capture a significant share if approved for Crohn’s.
Analysts project Omvoh could reach $3 billion in peak sales by 2030, assuming Crohn’s approval and steady uptake in ulcerative colitis. The new data strengthens that outlook, but Omvoh still trails Skyrizi in terms of market penetration. Skyrizi’s advantage lies in its established presence and broad label, including psoriasis and psoriatic arthritis.
What The New Data Means For Lilly’s Stock
Lilly’s stock has been on a tear in 2026, driven by its obesity and diabetes franchise, particularly Zepbound and Mounjaro. Omvoh is a smaller contributor, but the IBD data adds a new growth vector. On October 14, 2026, Lilly shares closed at $620.50, up 0.8% for the day. The stock is up 25% year-to-date, outperforming the S&P 500’s 12% gain.
AbbVie, meanwhile, has seen its stock pressured by concerns over Skyrizi’s growth trajectory. ABBV closed at $150.20 on October 14, down 0.3%. The company reports third-quarter earnings on October 30, 2026, and investors will be watching for any signs of competitive impact from Omvoh.
The Competitive Landscape And What To Watch
Beyond Skyrizi and Stelara, other players include Takeda’s Entyvio and Pfizer’s Xeljanz, but Omvoh’s IL-23 mechanism is considered best-in-class for durability. Lilly is expected to file for Crohn’s approval in the U.S. by the end of 2026, with a potential launch in mid-2027. The FDA decision will be a key catalyst.
Investors should also monitor reimbursement trends and real-world adherence data, as these will determine Omvoh’s commercial success. Lilly’s next earnings call on November 5, 2026, may provide updates on Omvoh’s launch metrics and pipeline progress.
If Omvoh secures Crohn’s approval and captures even 10% of the Crohn’s market, that could add $1.5 billion in annual sales, according to consensus estimates. The stock’s reaction will depend on how quickly Lilly can convert the data into market share. For now, the momentum is building.
Sources: seekingalpha.com · Eli Lilly · Investing.com · Yahoo Finance · Reuters